Cargando…
Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy
Glioblastoma (GBM) is a rapidly progressive brain cancer that exploits the neural microenvironment, and particularly blood vessels, for selective growth and survival. Anti-angiogenic agents such as the vascular endothelial growth factor-A (VEGF-A) blocking antibody bevacizumab yield short-term benef...
Autores principales: | Kwiatkowski, Sam C., Guerrero, Paola A., Hirota, Shinya, Chen, Zhihua, Morales, John E., Aghi, Manish, McCarty, Joseph H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609745/ https://www.ncbi.nlm.nih.gov/pubmed/28938007 http://dx.doi.org/10.1371/journal.pone.0185065 |
Ejemplares similares
-
Neuropilin 1 balances β8 integrin-activated TGFβ signaling to control sprouting angiogenesis in the brain
por: Hirota, Shinya, et al.
Publicado: (2015) -
Anti-angiogenic therapies in the management of glioblastoma
por: Schulte, Jessica D., et al.
Publicado: (2021) -
Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma
por: Jain, Saket, et al.
Publicado: (2022) -
Revisiting anti-angiogenic therapy for recurrent glioblastoma
por: Peters, Katherine B.
Publicado: (2019) -
TGF-β production by eosinophils drives the expansion of peripherally induced neuropilin(−) RORγt(+) regulatory T-cells during bacterial and allergen challenge
por: Fallegger, Angela, et al.
Publicado: (2022)